ACADIA named Pantheon DiNA Award recipient by CLSA

ACADIA Pharmaceuticals has been named the recipient of the 2016 Pantheon DiNA Award by the California Life Sciences Association (CLSA) for its therapeutic product NUPLAZID.

NUPLAZID is the only medication developed to treat hallucinations and delusions linked to psychosis associated with Parkinson’s disease to receive approval from the U.S. Food and Drug Administration.

“We are honored to be recognized for our team’s hard work and commitment to discovering, developing and commercializing NUPLAZID,” ACADIA President and CEO Steve Davis said. “NUPLAZID represents the culmination of many years of work across our entire organization, and we are gratified by the opportunity to improve the lives of people with Parkinson’s disease psychosis.”

The CLSA developed the Pantheon Awards to recognize the achievements and to honor brilliance in California’s life sciences industry. The award for the Outstanding Therapeutic Product is presented to the most significant or promising product in new life sciences.

“We are pleased to honor this first-in-class, first-in-disease medication with this year’s Pantheon DiNA Award for Outstanding Therapeutic Product,” CLSA President and CEO Sara Radcliffe said. “NUPLAZID truly represents the type of innovation and excellence for which the California life sciences sector is known.”